BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28807603)

  • 1. Stem cell industry update: 2012 to 2016 reveals accelerated investment, but market capitalization and earnings lag.
    Ng M; Song S; Piuzzi NS; Ng K; Gwam C; Mont MA; Muschler GF
    Cytotherapy; 2017 Oct; 19(10):1131-1139. PubMed ID: 28807603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics.
    Lysaght MJ; Jaklenec A; Deweerd E
    Tissue Eng Part A; 2008 Feb; 14(2):305-15. PubMed ID: 18333783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Industry highlights: Stem cell and regenerative medicine.
    Ilic D
    Regen Med; 2011 Nov; 6(6 Suppl):55-60. PubMed ID: 21999262
    [No Abstract]   [Full Text] [Related]  

  • 5. The need for a regen industry voice.
    Mason C; Dunnill P
    Regen Med; 2008 Sep; 3(5):621-31. PubMed ID: 18729785
    [No Abstract]   [Full Text] [Related]  

  • 6. Regenerative medicine and the developing world.
    Greenwood HL; Singer PA; Downey GP; Martin DK; Thorsteinsdóttir H; Daar AS
    PLoS Med; 2006 Sep; 3(9):e381. PubMed ID: 16968130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global update: USA.
    Matthews KR; Rowland ML
    Regen Med; 2012 Nov; 7(6 Suppl):126-9. PubMed ID: 23210825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stem cells: the blue print for the future.
    Mason C
    Med Device Technol; 2006 Apr; 17(3):32-3. PubMed ID: 16736663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2010 World Stem Cell Summit--part 1. October 4-6, 2010, Detroit, MI, USA.
    Vertès A
    IDrugs; 2010 Dec; 13(12):819-21. PubMed ID: 21154132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stem Cell and Regenerative Medicine Global Conference (SCRGC) 2016 (August 23-24, 2016 - Gyeonggi-do, Korea).
    Vertès A
    Drugs Today (Barc); 2016 Oct; 52(10):577-583. PubMed ID: 27910966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced Tissue Sciences Inc.: learning from the past, a case study for regenerative medicine.
    Pangarkar N; Pharoah M; Nigam A; Hutmacher DW; Champ S
    Regen Med; 2010 Sep; 5(5):823-35. PubMed ID: 20868336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health consumers and stem cell therapy innovation: markets, models and regulation.
    Salter B; Zhou Y; Datta S
    Regen Med; 2014 May; 9(3):353-66. PubMed ID: 24935045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administrative and research policies required to bring cellular therapies from the research laboratory to the patient's bedside.
    Yim R
    Transfusion; 2005 Oct; 45(4 Suppl):144S-58S. PubMed ID: 16181400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic and autologous mode of stem cell transplantation in regenerative medicine: which way to go?
    Mamidi MK; Dutta S; Bhonde R; Das AK; Pal R
    Med Hypotheses; 2014 Dec; 83(6):787-91. PubMed ID: 25456787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering the therapeutic stem cell strategies of large and midsize pharmaceutical firms.
    Vertès AA
    Regen Med; 2014; 9(4):479-95. PubMed ID: 25159065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in stem cells technologies and their commercialization potential.
    Kamarul T
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):363-5. PubMed ID: 23927663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell therapy companies make strong progress from October 2012 to March 2013 amid mixed stock market sentiment.
    Mason C; Mason J; Culme-Seymour EJ; Bonfiglio GA; Reeve BC
    Cell Stem Cell; 2013 Jun; 12(6):644-7. PubMed ID: 23746973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economic value of investing in regenerative medicine.
    Hussain A; Rivers PA
    J Health Care Finance; 2009; 36(2):45-54. PubMed ID: 20499720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Making stem cells count for global health.
    McMahon DS; Thorsteinsdóttir H
    Regen Med; 2011 Nov; 6(6 Suppl):163-6. PubMed ID: 21999282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global update: Canada.
    Willemse L; Ogbogu U; Johnson S; Rudnicki M
    Regen Med; 2012 Nov; 7(6 Suppl):132-5. PubMed ID: 23210826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.